36 results match your criteria: "Puget Sound Blood Center Research Institute[Affiliation]"
Transfusion
January 2014
Department of Pathology, Emory University, Atlanta, Georgia; Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University, Atlanta, Georgia; Puget Sound Blood Center Research Institute, Seattle, Washington.
In this issue of Blood, Sorvillo et al investigate possible molecular triggers leading to idiopathic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying naturally processed A Disintegrin And Metalloprotease with ThromboSpondin type 1 motif 13 (ADAMTS13)-derived peptides presented on human dendritic cells.
View Article and Find Full Text PDFArterioscler Thromb Vasc Biol
June 2013
Puget Sound Blood Center Research Institute, Seattle, WA 98102, USA.
Objective: Cocaine use is associated with arterial thrombosis, including myocardial infarction and stroke. Cocaine use results in increased plasma von Willebrand factor (VWF), accelerated atherosclerosis, and platelet-rich arterial thrombi, suggesting that cocaine activates the endothelium, promoting platelet-VWF interactions.
Approach And Results: Human umbilical vein endothelial cells, brain microvasculature endothelial cells, or coronary artery endothelial cells were treated with cocaine or metabolites benzoylecgonine, cocaethylene, norcocaine, or ecgonine methylester.
Transfusion
November 2013
Center for Clinical Transfusion Research, Sanquin Blood Supply, Leiden, The Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands; Jon J. van Rood Center for Clinical Transfusion Research, Leiden University Medical Center, Leiden, The Netherlands; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; Blood Transfusion, Pediatric and Point of Care, Clinical Chemistry and Hematology Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands; Puget Sound Blood Center Research Institute, Seattle, Washington.
Background: Red blood cells (RBCs) undergo changes during storage. Various studies have suggested a higher risk of adverse and often multifactorial clinical outcomes associated with older-stored RBCs. Our aim therefore was to examine if storage of transfused RBCs is also associated with the risk of RBC-specific alloantibody formation.
View Article and Find Full Text PDFTransfusion
October 2013
Puget Sound Blood Center Research Institute, Seattle, Washington; Laboratory of Transfusion Biology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York.
Transfusion
October 2013
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia; Puget Sound Blood Center Research Institute, Seattle, Washington; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio; Department of Pathology, University of Pittsburgh and the Institute for Transfusion Medicine, Pittsburgh, Pennsylvania.
Background: The storage of red blood cells (RBCs) results in numerous changes, which over time result in decreased recovery of transfused RBCs. In addition (at least in animal models), stored RBCs can be more immunogenic and also stimulate the systemic release of inflammatory cytokines in transfusion recipients. One component of the RBC storage lesion is the accumulation of oxidative damage.
View Article and Find Full Text PDFHematology Am Soc Hematol Educ Program
June 2013
Puget Sound Blood Center Research Institute, 921 Terry Ave, Seattle,WA 98104, USA.
Idiopathic (immune) thrombocytopenic purpura (ITP) is a common autoimmune disorder resulting in isolated thrombocytopenia. ITP can present either alone (primary) or in the setting of other conditions (secondary) such as infections or altered immune states. ITP is associated with a loss of tolerance to platelet antigens and a phenotype of accelerated platelet destruction and impaired platelet production.
View Article and Find Full Text PDFCurr Opin Hematol
September 2012
Puget Sound Blood Center Research Institute, Seattle, Washington 98104, USA.
Purpose Of Review: The review describes recent advances in our understanding of mechanisms leading to development of neutralizing antibodies following factor VIII (FVIII) replacement therapy for hemophilia A. Novel interventions with translational potential to lessen the incidence of these deleterious immune responses are discussed.
Recent Findings: Genetic and environmental risk factors for inhibitor development, and cellular mechanisms leading to antibody production versus immune tolerance to FVIII, are increasingly coming into focus.
Transfus Clin Biol
June 2012
Puget Sound Blood Center Research Institute, 1551, Eastlake Avenue E, Seattle, WA 98102, USA.
Transfused red blood cells, platelets, or coagulation factors have the capacity to induce alloantibodies, which once formed, can be a clinical barrier to future transfusion therapy and/or transplantation. Large observational studies over the last 50 years have characterized some of the general properties of transfusion induced alloimmunization, which appear to vary to a considerable extent from what is generally observed for human responses to other immunogens, such as microbial pathogens and vaccines. Transfused cells and factor only induce immune responses in the minority of recipients.
View Article and Find Full Text PDFBlood
June 2012
Puget Sound Blood Center Research Institute, University of Washington, WA, USA.